Xtant Medical Holdings, Inc.
XTNT- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001453593
No open-market purchases or sales by Xtant Medical Holdings, Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $62.6M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Xtant Medical Holdings, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Xtant Medical Holdings, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Lipschultz Tyler | Director | 373,745 | Aug 18, 2026 | 2 |
| Bakewell John K | Director | 1,129,633 | Aug 18, 2026 | 2 |
| Beeson Jonn R. | Director | 733,136 | Aug 18, 2026 | 2 |
| Jain Abhinav | Director | 373,745 | Aug 18, 2026 | 2 |
| Vizirgianakis Stavros G. | Director | 7,838,845 | Aug 18, 2026 | 2 |
| Schallenberger Mark A. | Chief Operating Officer | 1,106,087 | Aug 18, 2026 | 3 |
| Neils Scott C | CFO and Assistant Secretary | 1,215,226 | Aug 18, 2026 | 3 |
| Browne Sean E | President and CEO | 3,114,669 | Aug 18, 2026 | 2 |
| OrbiMed Advisors LLC | 10% Owner | 0Indirect | Apr 14, 2025 | 0 |
| Orbimed ROF II LLC | 10% Owner | 0Indirect | Apr 14, 2025 | 0 |
| Mitchell-Keller Lori D | Director | 353,124 | Aug 19, 2024 | 0 |
| McNamara Robert | Director | 754,151 | Aug 19, 2024 | 0 |
| Brandt Kevin D | Chief Commercial Officer | 943,736 | Aug 19, 2024 | 0 |
| Peters Jeffrey J | Director | 448,546 | Aug 17, 2022 | 0 |
| Rizzo Matthew | Director, 10% Owner | 215,415 | Aug 17, 2022 | 0 |
| Eggenberg Michael | Director, 10% Owner | 215,415 | Aug 17, 2022 | 0 |
| Jensen Greg | Vice President, Finance & CFO | 285,331 | Aug 17, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 14, 2025 (view filing)7:14 PM ET | Apr 10 | 4 days | OrbiMed Advisors LLC and 1 other10% Owner | SSale | −73.1M | $0.42 | −$30.7M | −100.0%0 after | 2 lots |
| Nov 17, 2023 (view filing) | Nov 17 | Same day | Brandt Kevin DChief Commercial Officer | PPurchase | +41.7K | $1.20 | +$50.0K | +5.4%815.9K after | |
| Jan 19, 2023 (view filing) | Jan 18 | 1 day | Neils Scott CChief Financial Officer | SSaleCommon Stock, $0.000001 par value | −8.67K | $0.61 | −$5.29K | −2.1%404.0K after | |
| Oct 20, 2022 (view filing) | Oct 18-19 | 2 days | Browne Sean EPresident and CEO | SSaleCommon Stock, $0.000001 par value | −131.1K | $0.6566 | −$86.1K | −8.0%1.51M after | 2 lots |
| Oct 11, 2022 (view filing)4:48 PM ET | Oct 7 | 4 days | Vizirgianakis Stavros G.Director | PPurchaseCommon Stock, $0.000001 par value | +2.26M | $0.48 | +$1.09M | +63.2%5.85M after | |
| Oct 11, 2022 (view filing)4:48 PM ET | Oct 7 | 4 days | Vizirgianakis Stavros G.Director | PPurchase | +566.2K | $0.00 | $0 | –566.2K after | Derivative |
| Aug 17, 2022 (view filing)5:28 PM ET | Aug 16-17 | 1 day | Brandt Kevin DChief Commercial Officer | SSaleCommon Stock, $0.000001 par value | −23.0K | $0.4879 | −$11.2K | −3.2%703.6K after | 2 lots |
| Aug 17, 2022 (view filing)5:10 PM ET | Aug 16-17 | 1 day | Neils Scott CChief Financial Officer | SSaleCommon Stock, $0.000001 par value | −6.37K | $0.4812 | −$3.07K | −1.5%412.6K after | 2 lots |